Brain+ begins early activity and brand building in the US
Brain+ begins early activity and brand building in the US The United States (US) is a key future market for Brain+, and early brand building and exploration is now ongoing Brain+ has been selected and […]
First milestone met
Brain+ meets milestone with Rox Health (Roche Germany) Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch. Meeting this milestone unlocks access for Brain+ to additional […]
New Research report values Brain+
New research report values Brain+ at DKK 4.1 per share in the base case, and DKK 6.4 in the bull case. The research report concludes that “Brain+ is in a strong position to grow towards […]
Accelerated launch Q2 2023
Brain+ partners with German medical distributor Advances launch of its first CST dementia product in Germany to Q2 2023 Through Coopmed, Brain+ will be represented by experienced and local medical sales managers in […]
Brain+’ new product for dementia launching Q4 2022
Brain+’ new product for dementia launching Q4 2022 Digital “CST–Therapist Companion” is launching one year ahead of plan The Brain+ “CST-Therapist Companion” is a new digital product to deliver Cognitive Stimulation Therapy […]
Growing interest in DTx from big pharma
Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia. Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other […]
Common Nordic digital health evaluation framework launched
Common Nordic digital health evaluation framework launched Digital Therapeutics (DTx) is a growing trend and is increasingly a recognized market providing an important supplement to the established trillion USD pharmaceutical market (traditional medicine). The DTx […]
Germany opens the DiPA reimbursement pathway
Germany opens the DiPA reimbursement pathway to support the adoption of digital health applications, underpinning the value of the #1 target market for Brain+’ first commercial dementia product, CST A significant event for Brain+ as […]
1m SEK FORTE grant project to map digital interventions for dementia
1m SEK FORTE grant project to map digital interventions for dementia Helping Brain+ strengthen patient and care giver compliance for product development PURPOSE: The FORTE project will perform a scoping review of digital interventions for […]
2021 Brain+ Annual Report
From the CEO: I am pleased with the Brain+ 2021 annual results we have presented today. With our commitment to develop medical software to detect and treat the cognitive symptoms of dementia, 2021 brought real […]